Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01035099 · ClinicalTrials.gov registry record · Phase 4
RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF
A Phase 4 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 4
- Development phase
- 41
- Enrollment target
NCT01035099 is a Phase 4 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 41 participants.
The verdict
NCT01035099, a Phase 4 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to compare two different ways to administer Letrozole to determine their effectiveness in blocking estrogen production during ovarian stimulation in patients with breast cancer prior to chemotherapy/radiotherapy so that oocytes or embryos can be cryopreserved and patients can possibly achieve a pregnancy after the treatment of breast cancer. During standard ovulation stimulation, the estrogen levels will exceed normal levels and may reach 10 times the normal level for a 2 week period. This may not be desirable in breast cancer patients. The study hopes to determine if the investigators can stimulate oocyte development in the conventional way and administer different doses of Letrozole as the oocytes develop, to keep estradiol levels low, increase the number of oocytes the investigators are able to recover, and improve the quality of those oocytes.
Interventions
- DRUG Letrozole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2009-11 |
| Est. Completion | 2022-09-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01035099
The ClinicalTrials.gov registry entry for NCT01035099 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Letrozole is the first listed.
NCT01035099 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01035099 about?
NCT01035099 is a clinical study titled "RCT of Fixed vs Titrated Letrozole in Breast Cancer Patient Undergoing IVF". The purpose of this study is to compare two different ways to administer Letrozole to determine their effectiveness in blocking estrogen production during ovarian stimulation in patients with breast cancer prior to chemotherapy/radiotherapy so that oocytes or embryos can be cryopreserved and patient...
What is the current status of trial NCT01035099?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 41 participants. The study started on 2009-11. Estimated completion is 2022-09-30.
What interventions are being tested in trial NCT01035099?
The interventions under investigation include: Letrozole (DRUG).
Who is sponsoring clinical trial NCT01035099?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.